Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 5/20 | 0.54 |
| ▸ | WNT3A | P56704 | 3/20 | 0.54 |
| ▸ | PLOD2 | O00469 | 3/20 | 0.53 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.53 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31081298 | 1.00 | CTNNB1 (0.54) | CTNNB1WNT3APLOD2PLOD3PLOD1 | |
| SCHEMBL253276 | 0.83 | CES2 (0.64) | CTNNB1WNT3ACES2CES1LMNA | |
| SCHEMBL29355245 | 0.83 | CES2 (0.64) | CTNNB1WNT3ACES2CES1LMNA | |
| SCHEMBL18622350 | 0.83 | ALDH1A1 (0.52) | CTNNB1WNT3ACES2CES1LMNA | |
| SCHEMBL33721999 | 0.80 | CES2 (0.59) | CTNNB1WNT3ACES2CES1LMNA | |
| SCHEMBL2544523 | 0.80 | CES2 (0.59) | CTNNB1WNT3ACES2CES1LMNA | |
| SCHEMBL9493294 | 0.78 | LMNA (0.61) | CTNNB1WNT3ACES2CES1LMNA | |
| SCHEMBL18622294 | 0.78 | PLOD2 (0.55) | CTNNB1WNT3APLOD2PLOD3PLOD1 | |
| SCHEMBL16181683 | 0.77 | PLOD2 (0.50) | CTNNB1WNT3APLOD2PLOD3PLOD1 | |
| SCHEMBL1360847 | 0.77 | ALDH1A1 (0.62) | CTNNB1WNT3ACES2CES1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024215863-A2 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-9595683-B2 | Organometallic compounds and organic light emitting devices including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-03-14 | — | — | US | disclosed |
| US-9595683-B2 | Organometallic compounds and organic light emitting devices including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-03-14 | — | — | US | disclosed |
| US-8586201-B2 | Light-emitting element and iridium complex | CHIMEI INNOLUX CORPORATION (TW) | 2013-11-19 | — | — | US | disclosed |
| US-8129396-B2 | 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-1506196-B1 | PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-2346856-A1 | 2-[1H-BENZIMIDAZOL-2(3H)-YLIDENE]-2-(PYRIMIDIN-2-YL)ACETAMIDES AND 2-[BENZOTHIAZOL-2(3H)-YLIDENE]-2-(PYRIMIDIN-2-YL)ACETAMIDES AS KINASE INHIBITORS | Telik, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1670801-B1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-20100141133-A1 | LIGHT-EMITTING ELEMENT AND IRIDIUM COMPLEX | CHI MEI OPTOELECTRONICS CORP. (TW) | 2010-06-10 | — | — | US | disclosed |
| US-20100141133-A1 | LIGHT-EMITTING ELEMENT AND IRIDIUM COMPLEX | CHI MEI OPTOELECTRONICS CORP. (TW) | 2010-06-10 | — | — | US | disclosed |
| US-20060228578-A1 | Phosphorescent iridium complexes | EASTMAN KODAK COMPANY | 2006-10-12 | — | — | US | disclosed |
| US-7098335-B2 | Pyrazolopyrimidine compositions | ICAGEN, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1670801-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-20050215569-A1 | Pyrazolopyrimidines | ICAGEN, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
| WO-2005040171-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| EP-1506196-A2 | PYRAZOLOPYRIMIDINES | Icagen, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6833371-B2 | Contacting cell with a sodium channel-inhibiting amount of a compound comprising a pyrazolopyrimidine moiety for decreasing ion flow through a voltage-dependent sodium channel in a cell | ICAGEN, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20030176450-A1 | Pyrazolopyrimidines | ICAGEN, INC. (US) | 2003-09-18 | — | — | US | disclosed |
| WO-2003037900-A2 | PYRAZOLOPYRIMIDINES | ICAGEN, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215569-A1 | Pyrazolopyrimidines | SCN3A, TRPV3, P2RX3 | CTNNB1 2105/4885WNT3A 1407/4885PLOD2 3754/4885 |
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | CTNNB1 3894/4885WNT3A 4345/4885PLOD2 3738/4885 |
| US-20030176450-A1 | Pyrazolopyrimidines | SCN3A, TRPV3, P2RX3 | CTNNB1 2105/4885WNT3A 1407/4885PLOD2 3754/4885 |
| US-20100141133-A1 | LIGHT-EMITTING ELEMENT AND IRIDIUM COMPLEX | AP3D1, INF2, CRY1 | CTNNB1 1304/4885WNT3A 3332/4885PLOD2 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.